The use of stromal vascular fraction (SVF), platelet-rich plasma (PRP) and stem cells in the treatment of osteoarthritis: an overview of clinical trials

Mehranfar, Sahar; Rad, Isa Abdi; Mostafav, Ebrahim; Akbarzadeh, Abolfazl

doi:10.1080/21691401.2019.1576710

Cited by 49 publications

(41 citation statements)

References 75 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to this concept, bone marrow- and adipose-derived stem cells have been examined in several preclinical studies [ 16 , 35 , 36 , 37 ]. However, at the levels of clinical research and clinical practice, such combinational treatments are limited [ 38 , 39 ]. The most successful example is the combination of tissue-engineered periosteal sheets and PRP.…”

Section: History Of Pc Studymentioning

confidence: 99%

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

2020

View full text Add to dashboard Cite

The ultimate goal of research on platelet concentrates (PCs) is to develop a more predictable PC therapy. Because platelet-rich plasma (PRP), a representative PC, was identified as a possible therapeutic agent for bone augmentation in the field of oral surgery, PRP and its derivative, platelet-rich fibrin (PRF), have been increasingly applied in a regenerative medicine. However, a rise in the rate of recurrence (e.g., in tendon and ligament injuries) and adverse (or nonsignificant) clinical outcomes associated with PC therapy have raised fundamental questions regarding the validity of the therapy. Thus, rigorous evidence obtained from large, high-quality randomized controlled trials must be presented to the concerned regulatory authorities of individual countries or regions. For the approval of the regulatory authorities, clinicians and research investigators should understand the real nature of PCs and PC therapy (i.e., adjuvant therapy), standardize protocols of preparation (e.g., choice of centrifuges and tubes) and clinical application (e.g., evaluation of recipient conditions), design bias-minimized randomized clinical trials, and recognize superfluous brand competitions that delay sound progress. In this review, we retrospect the recent past of PC research, reconfirm our ultimate goals, and discuss what will need to be done in future.

show abstract

Section: History Of Pc Studymentioning

confidence: 99%

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

2020

View full text Add to dashboard Cite

show abstract

“…Of all the available nanoparticles, gold nanoparticles with unique surface chemistry, ease of synthesis, possibility of extensive chemical modification, excellent biocompatibility as well as superior optical, electrical, and thermal properties have attracted tremendous attention as fascinating building blocks for numerous biomedical applications such as bacterial inhibition, drug and gene delivery, stem cell-based tissue engineering, photothermal therapy, biosensing and bioimaging 14–17. Gold nanoparticles (GNPs) have been found to be both oxidants and antioxidants in biological systems in a size-dependent manner.…”

Section: Introductionmentioning

confidence: 99%

<p>Would Colloidal Gold Nanocarriers Present An Effective Diagnosis Or Treatment For Ischemic Stroke?</p>

Amani¹,

Mostafavi²,

Alebouyeh³

et al. 2019

IJN

Self Cite

127

View full text Add to dashboard Cite

IntroductionThis study was conducted to evaluate OX26-PEG-coated gold nanoparticles (GNPs) (OX26@GNPs) as a novel targeted nanoparticulate system on cell survival after ischemic stroke.Materials and methodsDynamic light scattering (DLS), zeta sizer, and transmission electron microscopy (TEM) were performed to characterize the OX26@GNPs. The effect of OX26@GNPs on infarct volume, neuronal loss, and necroptosis was evaluated 24 h after reperfusion using 2, 3,5-Triphenyltetrazolium chloride (TTC) staining, Nissl staining and Western blot assay, respectively.ResultsConjugation of OX26-PEG to the surface of the 25 nm colloidal gold particles increased their size to 32±2 nm, while a zeta potential change of −40.4 to 3.40 mV remarkably increased the stability of the nanoparticles. Most importantly, OX26@GNPs significantly increased the infarcted brain tissue, while bare GNPs and PEGylated GNPs had no effect on the infarct volume. However, our results indicated an extension of necroptotic cell death, followed by cell membrane damage.ConclusionCollectively, our results showed that the presently formulated OX26@GNPs are not suitable nanocarriers nor contrast agents under oxidative stress for the diagnosis and treatment of ischemic stroke. Moreover, our findings suggest that the cytotoxicity of GNPs in the brain is significantly associated with their surface charge.

show abstract

“…Thus, for example, SVF may participate in the treatment of inflammation, fibrosis, and vasculopathy in systemic sclerosis [ 20 , 21 ]. Studies have also used SVF in musculoskeletal disease with long-term positive results in knee osteoarthritis [ 22 ] or recalcitrant Achilles tendinopathy compared to control groups [ 23 ]. SVF has also been used in more invasive procedures such as intramyocardial injection in patients who underwent chronic ischemic cardiomyopathy with a good safety profile and significant functional improvement [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods

François

Guy

Véran

et al. 2020

Cells

View full text Add to dashboard Cite

The therapeutic use of adipose-derived stromal vascular fraction (SVF) is expanding in multiple pathologies. Various processes have been proposed for manufacturing SVF but they must be revisited based on advanced therapy medicinal product (ATMP) regulations. We report here the development and validation of a fully good manufacturing practices (GMP)-compliant protocol for the isolation of SVF. Adipose tissue was collected from healthy volunteers undergoing lipoaspiration. The optimal conditions of collagenase digestion and washing were determined based on measurements of SVF cell viability, yield recovery, and cell subset distribution. Comparability of the SVF obtained using the newly developed manufacturing process (n = 6) and the Celution-based automated method (n = 33), used as a reference, was established using inter-donor analyses. Characteristics of SVF (n = 5) generated using both manufacturing protocols were analyzed for an intra-donor comparison. In addition, these comparisons also included the determination of colony-forming unit fibroblast frequency, in vitro angiogenic activity, and in vivo regenerative effects in a mouse ischemic cutaneous wound model. We successfully developed a process for the generation of SVF presenting higher cell viability and yield recovery compared to the Celution device-based protocol. Characteristics of the SVF including phenotype, capacity for angiogenesis, and wound-healing promotion attested to the comparability of the two manufacturing processes. We validated an optimized non-automated process that should allow for a GMP-compliant, more affordable, and reduced-cost strategy to exploit the potential of SVF-based regenerative therapies.

show abstract

The use of stromal vascular fraction (SVF), platelet-rich plasma (PRP) and stem cells in the treatment of osteoarthritis: an overview of clinical trials

Abstract: View related articles View Crossmark data Citing articles: 4 View citing articles The use of stromal vascular fraction (SVF), platelet-rich plasma (PRP) and stem cells in the treatment of osteoarthritis: an overview of clinical trials

Cited by 49 publications

References 75 publications

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

<p>Would Colloidal Gold Nanocarriers Present An Effective Diagnosis Or Treatment For Ischemic Stroke?</p>

Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods

Contact Info

Product

Resources

About